STAT3 and cancer: Although it is well known that STAT3 activation is involved in some features of cancer cells, STAT3 inhibitors have not been used to treat CRCs yet; however, there are inhibitors that have shown encouraging effectiveness in preclinical studies that have entered clinical trials [89,90].